Prahlad V Raninga

4PUBLICATIONS
3CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|May 19, 2026
Redox regulation of EGFR activation by thioredoxin reductase 3 drives resistance to EGFR inhibitors in triple-negative breast cancer.

|Mar 03, 2025
Correction: CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.

Prahlad V Raninga, Bijun Zeng, Davide Moi

|Dec 20, 2024
CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.

Prahlad V Raninga, Bijun Zeng, Davide Moi

|Dec 20, 2022
CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.

Xue Lu, Yaowu He, Rebecca L Johnston

Pageof 1

Frequent Collaborators

2 joint publications

Chelsea Mayoh

2 joint publications

Kum Kum Khanna

1 joint publications

Marco J Herold